One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The source phrase most recent refers to November 2012. This historical source has not been relabeled as current FDA or Stanford guidance.
Current-source disagreement: the selected U.S. label suggests dose reduction below an indexed CrCl of 20; the older handbook table reduces below 5. Both are attributed below; this is not a single reconciled threshold.
The handbook retains the selected usual dose in its 20-50 and 5-20 mL/min bands and halves the dose, without changing frequency, only below 5. This differs materially from the selected U.S. label's below-20 threshold. Do not merge the two cutoffs.
cefotaxime:rdh5-180-1 · Source locator: Dose in renal impairment
APD/CAPD is described as not dialysing cefotaxime; HD and high-flux treatment do, with the book referring to the <5 band. Its older continuous-therapy rows list 1-2 g every 12 hours for CAV/VVHD and 2 g every 12 hours for CVVHD/HDF. These lack a contemporary effluent-rate-specific validation.
cefotaxime:rdh5-180-2 · Source locator: Dose in patients undergoing renal replacement therapies
The book's separate fluid-flux discussion has not been implemented as a clearance calculator. The U.S. label and handbook disagreement is unresolved, not counted as corroboration.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=cefotaxime&s1=rdh5-180&h1=703847bedb49a5e4abb0e66033a162575cc1eeff40c679c079ce9445e97cd6e6